The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

With (almost) no fees and unlimited refunds for ATM charges, Novo business checking is a good option for small-business owners on the go. But Novo’s customer support is lacking, and you can’t ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The Federal Open Market Committee is widely expected to take a breather this afternoon, the first pause since it started cutting rates in September. As a result, investors' focus will be more attuned ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney ...